Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B | AJMC

Two promising drugs are moving toward US approval after clearing key regulatory hurdles. Zidesamtinib targets a specific lung cancer mutation, while bepirovirsen earned special FDA status as a potential first-of-its-kind